Eisai Co., Ltd. (TYO:4523)
4,638.00
+95.00 (2.09%)
Aug 15, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 202.65B JPY in the quarter ending June 30, 2025, with 7.21% growth. This brings the company's revenue in the last twelve months to 803.02B, up 9.43% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
803.02B
Revenue Growth
+9.43%
P/S Ratio
1.63
Revenue / Employee
73.56M
Employees
10,917
Market Cap
1,307.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.22B |
Takeda Pharmaceutical Company | 4,480.25B |
Daiichi Sankyo Company | 1,924.68B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Eisai News
- 8 days ago - Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
- 10 days ago - Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 10 days ago - Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs - Seeking Alpha
- 17 days ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 4 weeks ago - "URECE" (Dotinurad) Launched in China as a treatment for Gout - Benzinga
- 2 months ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 3 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha